{
    "paper_id": "PMC7217143",
    "metadata": {
        "title": "A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014A possible reference for coronavirus disease\u201019 treatment option",
        "authors": [
            {
                "first": "Tian\u2010Tian",
                "middle": [],
                "last": "Yao",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jian\u2010Dan",
                "middle": [],
                "last": "Qian",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Wen\u2010Yan",
                "middle": [],
                "last": "Zhu",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Yan",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "email": "wangyanwang@bjmu.edu.cn",
                "affiliation": {}
            },
            {
                "first": "Gui\u2010Qiang",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "email": "john131212@126.com",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "In recent years, novel coronavirus infections have emerged periodically in various countries around the world. Severe acute respiratory syndrome coronavirus (SARS\u2010CoV) occurred in 2002, infecting 8422 people and causing 916 deaths during the epidemic.\n1\n Middle East respiratory syndrome coronavirus (MERS\u2010CoV) was first identified in 2012.\n2\n At the end of December 2019, a total of 2499 laboratory\u2010confirmed cases of Middle East respiratory syndrome (MERS), including 861 associated deaths were reported globally.\n3\n At the end of 2019, novel coronavirus pneumonia (NCP) emerged in Wuhan and had spread rapidly. The pathogen was confirmed new coronavirus, which was officially named coronavirus disease\u201019 (COVID\u201019) by the World Health Organization (WHO). As of February 21, 2020, a total of 76 395 confirmed cases have been reported, and 2 348 patients are reported to have died. Currently, there is no specific antiviral treatment for COVID\u201019. Therefore, identifying drug treatment options as soon as possible is critical for the response to the COVID\u201019 outbreak.",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "SARS\u2010CoV, MERS\u2010CoV, and COVID\u201019 belong to the same genera of CoV and all are beta\u2010CoV. COVID\u201019 shares 79.5% sequence identity with SARS\u2010CoV.\n4\n Therefore, the existing treatment LPV for SARS and MERS may be helpful for developing COVID\u201019 therapeutics.",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "Proteinase is a key enzyme in CoV polyprotein processing. In recent years, research on SARS\u2010CoV and MERS\u2010CoV protease inhibitors has been carried out in vitro and in vivo. Lopinavir (LPV) is a proteinase inhibitor. Both peak (9.6 \u00b5g/mL) and trough (5.5 \u00b5g/mL) serum concentrations of LPV inhibit SARS\u2010CoV.\n5\n LPV also blocks a post\u2010entry step in the MERS\u2010CoV replication cycle.\n6\n Ritonavir (RTV) inhibits the CYP3A\u2010mediated metabolism of LPV, thereby increasing the serum concentration of LPV. Lopinavir/ritonavir (LPV/r) is a combination of lopinavir and ribavirin. The antiviral activity of LPV/r is similar to that of LPV alone, suggesting that the effect is largely driven by LPV.\n7\n, \n8\n In this review, we analyze the efficacy of LPV or LPV/r in patients with SARS\u2010CoV and MERS\u2010CoV, which can be a useful reference for COVID\u201019 treatment option.",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "An analysis of molecular dynamics simulations showed that the SARS\u2010CoV 3CLpro enzyme could be inhibited by the combination of lopinavir and ritonavir.\n9\n A binding analysis of the main SARS coronavirus proteinase with LPV showed that half of lopinavir is left outside the catalytic site, and the efficacy of lopinavir may be poor.\n10\n Another study showed that neither lopinavir nor ritonavir has an effect on the replication of SARS\u2010CoV.\n11\n\n",
            "cite_spans": [],
            "section": "In vitro studies of SARS ::: IN VITRO AND ANIMAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "However, studies have revealed that lopinavir has antiviral activity. The 50% effective inhibitory concentration (EC50) of LPV for the plaque reduction assay is 6 \u00b5g/mL in the Vero cell line. The selectivity index (SI) of LPV is 8 to 32.\n12\n In vitro activity against SARS\u2010CoV has been demonstrated for lopinavir at 4 \u00b5g/mL after 48 hours of incubation. Cytopathic inhibition has been achieved down to a concentration of lopinavir 1 \u00b5g/mL combined with ribavirin at 6.25 \u00b5g/mL and data suggested that this combination may be synergistic against SARS\u2010CoV in vivo.\n13\n\n",
            "cite_spans": [],
            "section": "In vitro studies of SARS ::: IN VITRO AND ANIMAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "There have been some animal studies of SARS,\n14\n however, no study of lopinavir or ritonavir has been performed.",
            "cite_spans": [],
            "section": "Animal studies of SARS ::: IN VITRO AND ANIMAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "In an in vitro study, LPV inhibited MERS\u2010CoV\u2010induced cytopathic effect (CPE) with an EC50 of 8.0 \u03bcM (SI = 3.1), and a maximal protective effect (89% inhibition) was observed at a dose of 12 \u03bcM.\n6\n However, an in vitro study showed that LPV was not effective. LPV showed a suboptimal EC50 in the initial cytopathic effect inhibition assay and was therefore not evaluated further.\n15\n Another in vivo study of MERS showed that EC50 values generated for lopinavir and ritonavir were 11.6 and 24.9 \u03bcM with CC50 values > 50 \u03bcM, the SI for LPV and RTV was > 4.3 and > 2, respectively.\n7\n Compared with remdesivir and interferon\u2010\u03b2 (IFN\u2010\u03b2), LPV has inferior in vitro antiviral activity. RTV does not significantly enhance the antiviral activity of LPV in vitro.\n7\n\n",
            "cite_spans": [],
            "section": "In vitro studies of MERS ::: IN VITRO AND ANIMAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "For the MERS\u2010CoV mouse model, prophylactic LPV/r combined with IFN\u2010\u03b2 slightly reduced the viral loads.\n7\n However, therapeutic LPV/r and IFN\u2010\u03b2 improved pulmonary function, but failed to reduce viral replication and lung hemorrhaging. This in vivo evidence is suggestive of the potential for LPV/r to treat MERS\u2010CoV infections. When LPV/r was combined with IFN\u2010\u03b2, the antiviral activity (EC50 = 160 IU/mL) was indistinguishable from that of IFN\u2010\u03b2 alone (EC50 = 175 IU/mL, P = .62). This suggests that the observed in vitro antiviral activity of the LPV/r\u2010IFN\u2010\u03b2 combination against MERS\u2010CoV is dominated by IFN\u2010\u03b2 when LPV/r is used at clinically relevant concentrations.",
            "cite_spans": [],
            "section": "Animal studies of MERS ::: IN VITRO AND ANIMAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "Chan et al\n16\n explored the therapeutic potential of LPV/r and/or IFN\u2010\u03b2 in common marmosets. Animals treated with LPV/r alone or in combination with interferon\u03b21b had better clinical scores, less weight reduction, and less pulmonary infiltrate than untreated animals. Furthermore, necropsied lung and extrapulmonary tissues from the treated group had lower mean viral loads than those from the control group.",
            "cite_spans": [],
            "section": "Animal studies of MERS ::: IN VITRO AND ANIMAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "The in vitro and animal studies of SARS and MERS are summarized in Table 1.",
            "cite_spans": [],
            "section": "Animal studies of MERS ::: IN VITRO AND ANIMAL STUDIES",
            "ref_spans": [
                {
                    "start": 73,
                    "end": 74,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "In a preliminary report, there were no deaths at 30 days after the onset of symptoms among 34 patients treated with LPV/r (400 mg ritonavir and 100 mg lopinavir) in combination with ribavirin initially, compared to 10% mortality in 690 patients taking only ribavirin. Twenty\u2010one percent of 33 patients who received LPV/r as a rescue therapy died, whereas 42% of 77 patients who received ribavirin alone died.\n17\n However, these results were given only as a presentation, and no formal paper was published. Thus, this evidence is not credible.",
            "cite_spans": [],
            "section": "SARS ::: CLINICAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "A retrospective matched cohort study including 1052 SARS patients (75 treated patients and 977 control patients) showed that the addition of LPV/r as an initial treatment was associated with a reduced death rate (2.3%) and intubation rate (0%) compared with that in a matched cohort who received standard treatment (11.0% and 15.6%, respectively, P < .05).\n18\n In addition, the rate and dose of pulsed methylprednisolone were decreased. These SARS patients were retrospectively matched with control subject. Matching was performed with respect to age, sex, the presence of comorbidities, lactate dehydrogenase level, and the use of pulsed steroid therapy. However, the mortality, oxygen desaturation, and intubation rates of the subgroup of patients who received lopinavir\u2010ritonavir as rescue therapy were not different from those in the matched cohort and patients who received an increased dose of pulsed methylprednisolone. This result suggests that the combination of lopinavir and ribavirin has a synergistic effect for the treatment of SARS; it may play an essential role in the early phase of the infection. The viral replication phase peaks around day 10.\n19\n LPV/r use within this replication window decreases the peak viral load and the subsequent immune response.",
            "cite_spans": [],
            "section": "SARS ::: CLINICAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "Another retrospective matched cohort study of SARS patient also revealed that the rate of acute respiratory distress syndrome (ARDS) or death was significantly lower in the LPV/r combination treatment group (1/41, 2.4%) than the historical controls (32/111, 28.8%) on day 21.\n13\n In addition, the LPV/r group had a progressive decrease in the viral load, an early rise in the lymphocyte count, a reduction in the cumulative dose of pulsed methylprednisolone, and fewer episodes of nosocomial infections. These findings show that LPV/r, when combined with ribavirin, may be an effective agent against SARS. The summary of the effects of LPV in SARS patients is shown in Table 2.",
            "cite_spans": [],
            "section": "SARS ::: CLINICAL STUDIES",
            "ref_spans": [
                {
                    "start": 675,
                    "end": 676,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "A MERS patient who received LPV/r, ribavirin, and interferon had a resolution of viremia after 2 days of treatment.\n20\n However, the patient eventually died from septic shock 2 months and 19 days after the initial diagnosis. Another 64\u2010year\u2010old MERS patient from Korea was also treated with LPV/r, ribavirin, and interferon. After 6 days of antiviral therapy, negative PCR result in the serum sample, sputum samples, and swab samples were achieved.\n21\n The patient was discharged on day 13 of admission after achieving complete recovery. These two simple cases may show that LPV is effective against MERS. However, they do not exclude the possibility of other combination therapies being effective or spontaneous improvement occurring. The treatment effect of LPV/r against MERS is still controversial.",
            "cite_spans": [],
            "section": "MERS ::: CLINICAL STUDIES",
            "ref_spans": []
        },
        {
            "text": "A retrospective study enrolled healthcare workers (HCWs) with high\u2010risk exposure to MERS\u2010CoV pre\u2010isolation pneumonia and revealed that an effective post\u2010exposure prophylaxis (PEP) strategy including LPV/r may limit the spread of infection.\n22\n PEP therapy was associated with a 40% decrease in the risk of infection with no severe adverse events during treatment. PEP therapy was a significant factor that reduced the risk of MERS\u2010CoV infection in HCWs. This finding may indirectly reflect the antiviral effect of LPV/r. Moreover, a combination regimen of interferon + ribavirin + LPV/r was recommended officially for MERS therapy in Korea, where MERS began to spread in 2015.\n23\n Without randomized controlled trials, determining treatment is difficult due to patient and treatment variability as well as a lack of appropriately matched controls. The combination of LPV/r and interferon was considered in a randomized control trial in Saudi Arabia.\n24\n Enrollment began in November 2016 and the results are not yet available. The summary of LPV research in MERS patients is shown in Table 3.",
            "cite_spans": [],
            "section": "MERS ::: CLINICAL STUDIES",
            "ref_spans": [
                {
                    "start": 1090,
                    "end": 1091,
                    "mention": "3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "There are no reported in vitro studies of COVID\u201019. Four patients with COVID\u201019 were given antiviral treatment including LPV/r. After treatment, three patients showed significant improvement in pneumonia\u2010associated symptoms, two of whom were confirmed to be COVID\u201019 negative and discharged, and one of whom was negative for the virus at the first test.\n25\n This study shows the positive effects of LPV/r therapy. Two reviews, including a Chinese review and communication showed that LPV may be drug treatment option for COVID\u201019.\n26\n, \n27\n However, a retrospective study enrolled 134 NCP patients revealed that there is no significant difference between LPV/r\u2010treated group (n = 52), Abidol\u2010treated group (n = 34), and control group (n = 48) in improving symptom or in reducing viral loads.\n28\n The negative rate of COVID\u201019 nucleic acid on the 7 day was 71.8%, 82.6%, and 77.1%, respectively (P = .79). The efficacy of LPV/r antiviral treatment warrants further verification in future studies. Nine randomized controlled trials of LPV/r in patients with COVID\u201019 have been registered in China up to February 22 (Table 4). Currently, the combination of LPV/r is a recommended antiviral regimen in the latest version of the Diagnosis and Treatment of Pneumonia Caused by COVID\u201019 issued by the National Health Commission of the People's Republic of China.",
            "cite_spans": [],
            "section": "COVID\u201019 ::: CLINICAL STUDIES",
            "ref_spans": [
                {
                    "start": 1120,
                    "end": 1121,
                    "mention": "4",
                    "ref_id": "TABREF3"
                }
            ]
        },
        {
            "text": "Currently, there are no FDA\u2010approved treatments for any human CoV infection. Upon the emergence of SARS\u2010CoV and MERS\u2010CoV, patients were administered off\u2010label antivirals. Most in vitro studies have shown that SARS\u2010CoV could be inhibited by LPV and that the EC50 of LPV is acceptable. Furthermore, two retrospective matched cohort studies of SARS patients revealed that LPV/r plays an essential role in the clinical outcome, especially in the early stage. LPV/r\u2010treatment alone or in combination with interferon had improved clinical outcomes in experiments involving common marmosets and in some MERS patient. However, we need to wait for more clinically valid evidence to confirm the positive value of LPV for COVID\u201019 treatment.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Although most of the data indicate the efficacy of LPV, adverse reactions should be kept in mind. Diarrhea, nausea, and asthenia are the most frequently reported reactions in patients receiving LPV therapy.\n5\n Elevated total bilirubin, triglyceride, and hepatic enzyme levels have also been reported.\n20\n, \n21\n A retrospective study of MERS showed that the most common symptoms and laboratory tests of LPV/r PEP were diarrhea (40.9%), nausea (40.9%), stomatitis (18.2%), fever (13.6%), anemia (45.0%), leukopenia (40.0%), and hyperbilirubinemia (100%).\n22\n However, the symptoms and laboratory tests returned to normal after LPV therapy ceased.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The protease inhibitor LPV could be an effective treatment based on the experience accumulated from the SARS and MERS outbreaks. The treatment of CoV patients with LPV/r improved their outcomes. LPV/r may be a potential treatment option for COVID\u201019. Additional studies are needed to gain further insights into the origin, tropism, and pathogenesis of COVID\u201019.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The authors declare that there are no conflict of interests.",
            "cite_spans": [],
            "section": "CONFLICT OF INTERESTS",
            "ref_spans": []
        },
        {
            "text": "TTY and JDQ wrote the article, include the concept of this article, definition of intellectual content, and data acquisition; WYZ contributed for data acquisition; YW and GQW designed and reviewed the manuscript for its intellectual content.",
            "cite_spans": [],
            "section": "AUTHOR CONTRIBUTIONS",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: A summary of in vitro and animal studies of SARS and MERS\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: A summary of the studies on the use of lopinavir therapy in SARS patients\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: A summary of the studies on the use of lopinavir therapy in MERS patients\n",
            "type": "table"
        },
        "TABREF3": {
            "text": "Table 4: Clinical trials of lopinavir (LPV) in patients with 2019\u2010new coronavirus (2019\u2010nCoV) registered in China (up to February 22)\n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "SARS: epidemiology",
            "authors": [],
            "year": 2003,
            "venue": "Respirology",
            "volume": "8",
            "issn": "suppl",
            "pages": "S9-S14",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia",
            "authors": [],
            "year": 2012,
            "venue": "N Engl J Med",
            "volume": "367",
            "issn": "19",
            "pages": "1814-1820",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin",
            "authors": [],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1038/s41586-020-2012-7"
                ]
            }
        },
        "BIBREF4": {
            "title": "Lopinavir",
            "authors": [],
            "year": 2000,
            "venue": "Drugs",
            "volume": "60",
            "issn": "6",
            "pages": "1380-1381",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Screening of an FDA\u2010approved compound library identifies four small\u2010molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture",
            "authors": [],
            "year": 2014,
            "venue": "Antimicrob Agents Chemother",
            "volume": "58",
            "issn": "8",
            "pages": "4875-4884",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS\u2010CoV",
            "authors": [],
            "year": 2020,
            "venue": "Nat Commun",
            "volume": "11",
            "issn": "1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics",
            "authors": [],
            "year": 2002,
            "venue": "AIDS",
            "volume": "16",
            "issn": "15",
            "pages": "2081-2083",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS\u2010CoV 3CL(pro) inhibitors",
            "authors": [],
            "year": 2008,
            "venue": "J Theor Biol",
            "volume": "254",
            "issn": "4",
            "pages": "861-867",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs",
            "authors": [],
            "year": 2004,
            "venue": "Bioorg Med Chem",
            "volume": "12",
            "issn": "10",
            "pages": "2517-2521",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "HIV protease inhibitor nelfinavir inhibits replication of SARS\u2010associated coronavirus",
            "authors": [],
            "year": 2004,
            "venue": "Biochem Biophys Res Commun",
            "volume": "318",
            "issn": "3",
            "pages": "719-725",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds",
            "authors": [],
            "year": 2004,
            "venue": "J Clin Virol",
            "volume": "31",
            "issn": "1",
            "pages": "69-75",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings",
            "authors": [],
            "year": 2004,
            "venue": "Thorax",
            "volume": "59",
            "issn": "3",
            "pages": "252-256",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Virology: SARS virus infection of cats and ferrets",
            "authors": [],
            "year": 2003,
            "venue": "Nature",
            "volume": "425",
            "issn": "6961",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Broad\u2010spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus",
            "authors": [],
            "year": 2013,
            "venue": "J Infect",
            "volume": "67",
            "issn": "6",
            "pages": "606-616",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Treatment with lopinavir/ritonavir or interferon\u2010beta1b improves outcome of MERS\u2010CoV infection in a nonhuman primate model of common marmoset",
            "authors": [],
            "year": 2015,
            "venue": "J Infect Dis",
            "volume": "212",
            "issn": "12",
            "pages": "1904-1913",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS",
            "authors": [],
            "year": 2003,
            "venue": "JAMA",
            "volume": "290",
            "issn": "13",
            "pages": "1695-1696",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study",
            "authors": [],
            "year": 2003,
            "venue": "Hong Kong Med J",
            "volume": "9",
            "issn": "6",
            "pages": "399-406",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Clinical progression and viral load in a community outbreak of coronavirus\u2010associated SARS pneumonia: a prospective study",
            "authors": [],
            "year": 2003,
            "venue": "Lancet",
            "volume": "361",
            "issn": "9371",
            "pages": "1767-1772",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen",
            "authors": [],
            "year": 2014,
            "venue": "Int J Antimicrob Agents",
            "volume": "44",
            "issn": "6",
            "pages": "528-532",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Combination therapy with lopinavir/ritonavir, ribavirin and interferon\u2010alpha for Middle East respiratory syndrome",
            "authors": [],
            "year": 2016,
            "venue": "Antivir Ther",
            "volume": "21",
            "issn": "5",
            "pages": "455-459",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Post\u2010exposure prophylaxis for Middle East respiratory syndrome in healthcare workers",
            "authors": [],
            "year": 2019,
            "venue": "J Hosp Infect",
            "volume": "101",
            "issn": "1",
            "pages": "42-46",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Antiviral treatment guidelines for Middle East respiratory syndrome",
            "authors": [],
            "year": 2015,
            "venue": "Infect Chemother",
            "volume": "47",
            "issn": "3",
            "pages": "212-222",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon\u2010beta1b (MIRACLE trial): statistical analysis plan for a recursive two\u2010stage group sequential randomized controlled trial",
            "authors": [],
            "year": 2020,
            "venue": "Trials",
            "volume": "21",
            "issn": "1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment",
            "authors": [],
            "year": 2020,
            "venue": "Biosci Trends",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.5582/bst.2020.01030"
                ]
            }
        },
        "BIBREF25": {
            "title": "Potential antiviral therapeutics for 2019 novel coronavirus",
            "authors": [],
            "year": 2020,
            "venue": "Zhonghua Jie He He Hu Xi Za Zhi",
            "volume": "43",
            "issn": "0",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Drug treatment options for the 2019\u2010new coronavirus (2019\u2010nCoV)",
            "authors": [],
            "year": 2020,
            "venue": "Biosci Trends",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.5582/bst.2020.01020"
                ]
            }
        },
        "BIBREF27": {
            "title": "Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia",
            "authors": [],
            "year": 2020,
            "venue": "Chin J Infect Dis",
            "volume": "38",
            "issn": "0",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}